

Christian Pagnoux

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/616363/christian-pagnoux-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

7,768
citations

37
h-index

87
g-index

169
ext. papers

9,830
ext. citations

5.6
avg, IF

5.72
L-index

#	Paper	IF	Citations
149	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152021	5.3	
148	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022 , 11, e27273	2.1	
147	Pregnancy outcomes in women with primary systemic vasculitis: a retrospective study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 34, 2771-2777	2	5
146	Cessation of immunosuppressive therapies in patients with Takayasu arteritis with sustained inactive disease.. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 52, 151934-151934	5.3	
145	A Tale of 2 Aneurysms: Cardiogenic Shock Secondary to Vascular Behçet's Syndrome.. <i>JACC: Case Reports</i> , 2021 , 3, 1858-1862	1.2	
144	Pulmonary Involvement in Primary Systemic Vasculitides. <i>Rheumatology</i> , 2021 ,	3.9	2
143	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 339-346	5.3	8
142	Update on Maintenance Therapies for ANCA-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2021 , 7, 112	1.3	
141	Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives. <i>International Journal of Rheumatology</i> , 2021 , 2021, 5534851	2	3
140	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021 , 3, 404-412	3.5	4
139	Avacopan for the treatment of ANCA-associated vasculitis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 717-726	5.1	6
138	Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. <i>ACR Open Rheumatology</i> , 2021 , 3, 484-494	3.5	2
137	Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2021 ,	3.9	1
136	Facteurs prédictifs d'événements cardiovasculaires mortels et non mortels dans la vascularite à ANCA : données de la cohorte Toronto CanVasc. <i>Revue Du Rhumatisme (Edition Française)</i> , 2021 , 88, 279-283	0.1	
135	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2021 , 73, 641-650	9.5	3
134	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. <i>Journal of Rheumatology</i> , 2021 , 48, 555-566	4.1	11
133	Granulomatosis with polyangiitis presenting as pancreatic disease. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	1

132	Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020. <i>Journal of Rheumatology</i> , 2021 , 48, 1755-1756	4.1	
131	ANCA status and renal parameters at month 12 post-diagnosis can help predict subsequent relapses in patients with granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1011-1015	5.3	0
130	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1134-1138	5.3	2
129	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 114-118	2.2	2
128	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 119-124	2.2	1
127	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 119-124	2.2	
126	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 114-118	2.2	2
125	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020 , 21, 362	2.8	7
124	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1243-1249	2.4	22
123	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020 , 382, 622-631	59.2	211
122	Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: Data from the Toronto CanVasc cohort. <i>Joint Bone Spine</i> , 2020 , 87, 221-224	2.9	5
121	Characteristics of Takayasu Arteritis Patients with Severe Ischemic Events. <i>Journal of Rheumatology</i> , 2020 , 47, 1224-1228	4.1	2
120	Granulomatosis with Polyangiitis. <i>Rare Diseases of the Immune System</i> , 2020 , 97-129	0.2	0
119	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 576-581	5.3	6
118	Management of cutaneous vasculitis. <i>Presse Medicale</i> , 2020 , 49, 104033	2.2	7
117	Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1233-1239	2.3	1
116	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2020 , 2, 662-671	3.5	24
115	Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	5

114	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1314-1325	5.3	6
113	Pregnancy Outcomes in Systemic Vasculitides. <i>Current Rheumatology Reports</i> , 2020 , 22, 63	4.9	2
112	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 1001-1010	4.1	9
111	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1615-1624	4.7	32
110	Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 124, 171-175	2.2	1
109	355. FACTORS PREDICTING SEVERE INFECTIONS IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIDES BASED ON DATA FROM 733 PATIENTS ENROLLED IN RANDOMIZED CONTROLLED TRIALS. <i>Rheumatology</i> , 2019 , 58,	3.9	1
108	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019 , 58, 2203-2211	3.9	21
107	Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 617-630	5.4	10
106	Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. <i>Rheumatology</i> , 2019 , 58, 2107-2116	3.9	16
105	083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS. <i>Rheumatology</i> , 2019 , 58,	3.9	3
104	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019 , 46, 928-934	4.1	3
103	Presentation and Disease Course of Childhood-Onset Versus Adult-Onset Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 315-323	9.5	22
102	Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 939-949	5.1	2
101	Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. <i>Rheumatology</i> , 2019 , 58, 2333-2335	3.9	8
100	Hidradenitis suppurativa and vasculitis: A case series and literature review of a rare association. <i>SAGE Open Medical Case Reports</i> , 2019 , 7, 2050313X19882852	0.7	1
99	Microscopic polyangiitis and granulomatosis with polyangiitis 2019 , 153-172		0
98	Advances in the diagnosis of giant cell arteritis. <i>Current Opinion in Ophthalmology</i> , 2019 , 30, 407-411	5.1	3
97	Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019 , 58, 963-968	3.9	28

96	Diagnosis and management of ADA2 deficient polyarteritis nodosa. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22 Suppl 1, 69-77	2.3	17
95	Infection-associated vasculitides. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22 Suppl 1, 109-115	2.3	10
94	Comments on the giant cell arteritis probability score. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 117, 150	2.2	
93	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1150-1156	2.4	77
92	Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018 , 17, 683-693	13.6	27
91	Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. <i>Kidney International Reports</i> , 2018 , 3, 671-676	4.1	4
90	Prognostic Significance of Cavitory Lung Nodules in Granulomatosis With Polyangiitis (Wegener's): A Clinical Imaging Study of 225 Patients. <i>Arthritis Care and Research</i> , 2018 , 70, 1082-1089	4.7	10
89	Reply. <i>Arthritis and Rheumatology</i> , 2018 , 70, 151-152	9.5	1
88	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018 , 17, 653-659	13.6	34
87	Conventional and biological immunosuppressants in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 94-111	5.3	6
86	Impact of vasculitis on employment and income. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 111, 58-64	2.2	4
85	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018 , 17, 108-114	13.6	29
84	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018 , 13, e0205768	3.7	5
83	Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. <i>Rheumatology Advances in Practice</i> , 2018 , 2, rky026	1.1	8
82	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018 , 3, 1039-1049	4.1	25
81	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 846-853	9.5	82
80	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 837-845	9.5	155
79	Actualité thérapeutiques de la granulomatose avec polyangite (Wegener) et de la polyangite microscopique. <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 242-248	0	3

78	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1662-1668	2.4	100
77	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1054-1066	9.5	85
76	Childhood Takayasu arteritis: disease course and response to therapy. <i>Arthritis Research and Therapy</i> , 2017 , 19, 255	5.7	37
75	Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey. <i>Open Access Rheumatology: Research and Reviews</i> , 2017 , 9, 91-99	2.4	6
74	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2175-2186	9.5	78
73	Concordance of Time-of-Flight MRA and Digital Subtraction Angiography in Adult Primary Central Nervous System Vasculitis. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1917-1922	4.4	9
72	Investigational drugs in systemic vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1049-1061	5.9	4
71	High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017 , 69, 161-168	9.5	53
70	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017 , 16, 1-9	13.6	98
69	Gastrointestinal aspects of vasculitides. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 185-194	12.4	16
68	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e50	7.6	15
67	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 103, 176-184	2.2	5
66	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 475-82	5.3	73
65	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 690-701	9.5	78
64	Severe Intracranial Involvement in Giant Cell Arteritis: 5 Cases and Literature Review. <i>Journal of Rheumatology</i> , 2016 , 43, 648-56	4.1	35
63	Pharmacological approaches to CNS vasculitis: where are we at now?. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 109-16	3.8	7
62	A small n sequential multiple assignment randomized trial design for use in rare disease research. <i>Contemporary Clinical Trials</i> , 2016 , 46, 48-51	2.3	20
61	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. <i>Journal of Rheumatology</i> , 2016 , 43, 97-120	4.1	47

60	Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in an elderly woman. <i>Canadian Family Physician</i> , 2016 , 62, 635-7	0.9	
59	Updates in ANCA-associated vasculitis. <i>European Journal of Rheumatology</i> , 2016 , 3, 122-133	1.7	87
58	Patient-driven online survey on the clinical manifestations and diagnostic delay of granulomatosis with polyangiitis. <i>Joint Bone Spine</i> , 2016 , 83, 599-600	2.9	2
57	Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 1059-67	5.1	14
56	Letter by de Boysson and Pagnoux Regarding Article, "Diagnostic Yield and Safety of Brain Biopsy for Suspected Primary Central Nervous System Angiitis". <i>Stroke</i> , 2016 , 47, e256	6.7	4
55	Reply to: Importance of immunisation of elderly subjects before immunosuppressive treatment. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S21	2.2	24
54	Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S54-9 ²		4
53	Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S89-92	2.2	7
52	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015 , 26, 545-3 ⁹		254
51	Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1959-65	9.5	39
50	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015 , 54, 1351-9	3.9	32
49	Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's): A Report on 26 Cases. <i>Medicine (United States)</i> , 2015 , 94, e1088	1.8	40
48	Polyarteritis nodosa [Challenges and options in management. <i>Indian Journal of Rheumatology</i> , 2015 , 10, S64-S71	0.5	1
47	Ear, nose, and throat involvement in eosinophilic granulomatosis with polyangiitis. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2015 , 3, 27181		2
46	Vasculitis research: Don't slow down and plan for a life-time commitment. <i>Presse Medicale</i> , 2015 , 44, e221-2	2.2	
45	CanVasc recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides - Executive summary. <i>Canadian Journal of Kidney Health and Disease</i> , 2015 , 2, 43	2.3	9
44	Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1117-27	9.5	101
43	Treatment of granulomatosis with polyangiitis (Wegener's). <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 339-48	5.1	11

42	Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire. <i>Open Rheumatology Journal</i> , 2015 , 9, 16-20	0.2	5
41	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014 , 13, 197-205	13.6	61
40	Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. <i>Joint Bone Spine</i> , 2014 , 81, 337-41	2.9	20
39	Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2014 , 371, 1771-80	59.2	573
38	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 681-8	5.3	11
37	The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e115026	3.7	22
36	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013 , 43, 60-9	15.5	123
35	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013 , 65, 270-81		488
34	L38. How to treat primary vasculitis of the central nervous system. <i>Presse Medicale</i> , 2013 , 42, 605-7	2.2	3
33	Fertility and pregnancy in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 79-94	5.3	27
32	Vasculitis of the upper airways. <i>Swiss Medical Weekly</i> , 2012 , 142, w13541	3.1	17
31	CNS involvement in acute posterior multifocal placoid pigment epitheliopathy. <i>Canadian Journal of Neurological Sciences</i> , 2011 , 38, 526-8	1	8
30	Encrusting cystitis due to <i>Corynebacterium urealyticum</i> in a patient with ANCA-associated vasculitis: case report and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 297-300	5.3	16
29	Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. <i>Rheumatology</i> , 2011 , 50, 953-61	3.9	51
28	Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. <i>Journal of Rheumatology</i> , 2011 , 38, 475-8	4.1	32
27	The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. <i>Medicine (United States)</i> , 2011 , 90, 19-27	1.8	505
26	Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2381-8	27.4	393
25	Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. <i>Rheumatology</i> , 2010 , 49, 2181-90	3.9	50

24	Extraocular manifestations of birdshot chorioretinopathy in 118 French patients. <i>Presse Medicale</i> , 2010 , 39, e97-e102	2.2	13
23	Churg-Strauss syndrome: evidence for disease subtypes?. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 21-8	5.3	70
22	Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. <i>Joint Bone Spine</i> , 2010 , 77, 604-7	2.9	9
21	Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. <i>Arthritis and Rheumatism</i> , 2010 , 62, 616-26		360
20	Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1186-97		147
19	Churg-Strauss syndrome: evolving concepts. <i>Discovery Medicine</i> , 2010 , 9, 243-52	2.5	24
18	Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2008 , 359, 2790-803	59.2	468
17	Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. <i>Arthritis and Rheumatism</i> , 2008 , 58, 308-17		130
16	Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2908-18		180
15	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007 , 57, 686-93		193
14	Atherosclerosis in ANCA-associated vasculitides. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1107, 11-21	6.5	22
13	Therapeutic strategies for systemic necrotizing vasculitides. <i>Allergology International</i> , 2007 , 56, 105-11	4.4	21
12	Churg-Strauss syndrome. <i>Current Opinion in Rheumatology</i> , 2007 , 19, 25-32	5.3	159
11	Plasma exchange for systemic lupus erythematosus. <i>Transfusion and Apheresis Science</i> , 2007 , 36, 187-93	2.4	17
10	Indication for plasma exchange for systemic necrotizing vasculidities. <i>Transfusion and Apheresis Science</i> , 2007 , 36, 179-85	2.4	15
9	Cutaneous granulomatous vasculitis and extravascular granulomas. <i>Expert Review of Dermatology</i> , 2006 , 1, 315-326		3
8	Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. <i>Medicine (United States)</i> , 2005 , 84, 115-128	1.8	254
7	Peripheral neuropathy in systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 41-8	5.3	61

6	Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. <i>Medicine (United States)</i> , 2005 , 84, 313-322	1.8	284
5	Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. <i>Annals of Internal Medicine</i> , 2005 , 143, 632-8	8	449
4	How can patient care be improved beyond medical treatment?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 337-44	5.3	15
3	Churg-Strauss Syndrome and Leukotriene-Modifying Agents. <i>Clinical Pulmonary Medicine</i> , 2004 , 11, 349-354	5.4	6
2	When should immunosuppressants be prescribed to treat systemic vasculitides?. <i>Internal Medicine</i> , 2003 , 42, 313-7	1.1	26
1	Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome) 252-262		